The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant (EGFRm+) non–small-cell lung cancer (NSCLC) with central nervous system (CNS) metastasis.
 
Yi-Long Wu
Honoraria - AstraZeneca; BeiGene Beijing; Boehringer Ingelheim; Bristol-Myers Squibb/China; Hengrui Pharmaceutical; Lilly; MSD Oncology; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Roche; Takeda
Research Funding - BMS (Inst); Boehringer Ingelheim (Inst); Pfizer (Inst); Roche (Inst)
 
Qing Zhou
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly O.; MSD; Pfizer; Roche; Sanofi
 
Jie Wang
No Relationships to Disclose
 
Yan Yu
No Relationships to Disclose
 
Ligang Xing
No Relationships to Disclose
 
Ying Wang
No Relationships to Disclose
 
Ying Cheng
No Relationships to Disclose
 
Yueyin Pan
No Relationships to Disclose
 
Yun Fan
No Relationships to Disclose
 
Jianhua Shi
No Relationships to Disclose
 
Guojun Zhang
No Relationships to Disclose
 
Jiuwei Cui
No Relationships to Disclose
 
Jianying Zhou
Consulting or Advisory Role - Hansoh Pharma
Research Funding - Hansoh Pharma (Inst)
 
Yong Song
No Relationships to Disclose
 
Wu Zhuang
No Relationships to Disclose
 
Zhiyong Ma
No Relationships to Disclose
 
Yanping Hu
No Relationships to Disclose
 
Gaofeng Li
No Relationships to Disclose
 
Xiaorong Dong
No Relationships to Disclose
 
Myung-Ju Ahn
Honoraria - Amgen; AstraZeneca; Lilly; Merck Serono; MSD; TAKEDA; YUHAN
Consulting or Advisory Role - Alpha pharmaceutical; Amgen; AstraZeneca; Lilly; Merck Serono; MSD; Pfizer; TAKEDA; YUHAN
Research Funding - YUHAN